2 3例患者肿瘤免疫微环境结果提示:病例1cd8+淋巴细胞高度浸润,pd-l1阳性细胞在cd68+巨噬细胞中占比超过80% 使用臻和朗蒂思对3例患者肿瘤组织的免疫微环境进行检测。病例1肿瘤区cd8+和cd8+pd-1+ t细胞的百分比分别为8.6%和2.7%,间...
Using tissue microarrays from a retrospective cohort of TNBC patients from St George Hospital, Sydney (n=244), multiplexed immunofluorescence (mIF) was used to assess staining for CD3, CD8, CD20, CD68, PD-1, PD-L1, FOXP3 and pan-cytokeratin on the Vectra Polaris platform and analysed using...
著低于CD68低表达患者平均生存时间36个月，OS为63.2%，差异有统计学意义（P<0.05）；TAMs PD-L1高表达患者平均生存时间为25个月，OS为33.3%，显著低于TAMs PD-L1低表达患者平均生存时间37个月，OS为53.9%，差异有统计学意义（P<0.05）。结论 CD68、PD-L1在胃癌组织中高表达，CD68、PD-L1高表达患者平 ...
CD8、CD68、FoxP3、PD1和PD-L1在子宫内膜癌组织中的表达及临床意义 作者简介:李海军,男,副主任技师,主要从事临床检验研究.本文引用格式:李海军,边沁,何先伟．C D ８㊁C D ６８㊁F o x P ３㊁P D １和P D ＧL １在子宫内膜癌组织中的表达及临床意义[J ]．国际检验医学杂志,２０２１,４２(１０):...
Dual impacts of serine/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation Authors - Huan Tong View Article Cell Metab Pharmacological inhibition of arachidonate 12-lipoxygenase ameliorates myocardial ischemia-reperfusion injury in multiple species. Authors - Xiao...
PD-L1 expression and tumor-associated macrophage (TAM) status in phyllodes tumors (PT) have only been examined in a limited number of studies. This study aimed to investigate the expression of PD-L1 and TAM in breast PT and examine their implications.#Tissue microarrays were constructed from 18...
恶性黑色素瘤组织中PD-L1的蛋白表达阳性率为43.3%(26/60),与患者的总生存期(OS)差异无统计学意义(P0.05),与年龄,性别,发病部位,临床分期,肿瘤浸润深度,有无淋巴结转移及有无溃疡/坏死差异也无统计学意义,但PD-L1蛋白表达与肿瘤T分期差异有统计学意义(P0.05).3.恶性黑色素瘤组织中BRAFV600E蛋白表达阳性率...
CD133、CD68和PD-L1在不同病理级别脑胶质瘤组织中的表达及相关性 陈昊;莫立根;邓腾;栾方堃;于亚男;于海跃;田敏 【摘要】目的 探讨人脑胶质瘤组织中胶质瘤干细胞(glioma stem cells,GSCs)标志物CD133、肿瘤相关巨噬细胞(tumor-associated macrophages,TAMs)标志物CD68和负性共刺激分子PD-L1在不同病理级别人脑...
摘要 目的分析PD-L1、BRAFV600E、CD68蛋白和肿瘤浸润淋巴细胞(TIL)在恶性黑色素瘤诊断中的意义。方法应用高通量组织芯片技术及免疫组化方法,检测60例原发性恶性黑色素瘤组织中PD-L1、B...展开更多 Objective To analyze the significance of PD-L1,BRAFV600E,CD68 protein expressions and tumor infiltrating ...
For example, the PD-1/PD-L1 signaling pathway plays a vital role in the inhibition of immune responses and induction of apoptosis. Several studies have indicated that specific antibodies or drugs that target the PD-1/PD-L1 axis can effectively promote antitumor immunotherapy and lead to a ...